Categories
FAQ Imaging Medical Tests Patient Events

Inside Your Scans: How CT, PET/CT, MRI and Ultrasound Guide Blood Cancer Care

Inside Your Scans

How CT, PET/CT, MRI and Ultrasound Guide Blood Cancer Care

Let’s make scans less scary (and less painful) together!

Scans can bring a lot of worry. Join expert radiologists Dr. Robyn Stacy Humphries (Charlotte Radiology) and Dr. David Prologo (Winship Cancer Institute of Emory University) to learn what each imaging test really shows and how to stay calm before, during, and after your appointment.

They’ll both share how CT, PET/CT, MRI, and ultrasound help diagnose and monitor blood cancers such as lymphoma, CLL, and myeloma. Learn more about what each test shows and what results may mean for treatment.

Program Topics

  • Imaging 101: Ultrasound, CT, PET/CT, and MRI—what each shows and when it’s used
  • Image-Guided Biopsies: How radiologists target tissue safely and why repeat biopsies matter
  • Ports vs. Central Lines: Options for easier chemotherapy, blood draws, and comfort
  • Managing Scanxiety: Coping strategies while waiting for imaging or results
  • Teamwork in Care: How radiologists, oncologists, and tumor boards coordinate decisions
Dr. Robyn Stacy Humphries (Charlotte Radiology) joins Dr. David Prologo (Winship Cancer Institute of Emory University)
CLL Society

Categories
CLL Patient Events

Building a CLL Game Plan: Strategies for Treatment, Trials, and Team Building

Building a CLL Game Plan

Strategies for Treatment, Trials, and Team Building

Chronic lymphocytic leukemia (CLL) care is more personalized than ever.

CLL patient advocate Jeff Folloder and expert hematologist-oncologist Dr. Nicole Lamanna (Columbia University Irving Medical Center) explain how today’s innovative targeted therapies, time-limited treatment options, and emerging clinical trials can help patients craft a care strategy that truly fits their needs. The conversation dives into how to assemble a strong, collaborative medical team, at both local hospitals and major centers, so patients and families feel empowered at every step.

Program Topics

  • Set Your Treatment Strategy: Understand targeted therapies (BTK and BCL-2 inhibitors), their benefits, and when time-limited options fit your journey
  • Explore Clinical Trials: Discover how and where clinical trials fit in the CLL landscape, plus how to find the right match—whether at a major center or community clinic
  • Build an Empowered Team: Learn how to connect with local doctors and specialists from top centers for a coordinated plan, and what roles nurses, advocates, and social workers play
  • Get Organized: Practical tips for tracking labs, sharing results, and communicating with your care team
  • Prioritize Quality of Life: Find resources to manage daily challenges like fatigue, infection risk, and stress, while keeping your goals central to treatment talks
  • Join Your CLL Community: How support groups and partnerships can boost health literacy, advocacy, and your decision-making power

CLL Society

We would like to thank Blood Cancer United and the CLL Society for their partnerships.

This interview has been edited for clarity and length. This is not medical advice. Please consult with your healthcare provider for treatment decisions.


AbbVie

Thank you to AbbVie for its support of our independent patient education program. The Patient Story retains full editorial control over all content.

Building a CLL Game Plan: Strategies for Treatment, Trials, and Team Building
Hosted by The Patient Story Team
Chronic lymphocytic leukemia (CLL) care is more personalized than ever. Patient advocate Jeff Folloder and expert hematologist-oncologist Dr. Nicole Lamanna (Columbia University Irving Medical Center) explain how today’s innovative targeted therapies, time-limited treatment options, and emerging clinical trials can help patients craft a care strategy that truly fits their needs.
Powered by
Powered by
Categories
Ovarian Cancer Patient Events

A New Era in Ovarian Cancer Treatment and Platinum-Resistant Options

A New Era in Platinum-Resistant Ovarian Cancer Treatment Options

Wednesday, September 24th 5pm PT / 8pm ET

Navigating a diagnosis of platinum-resistant ovarian cancer can feel overwhelming, but recent advancements and clinical trials are bringing new hope and more personalized treatment paths. This program offers empowering information on the latest therapies. We are joined by Dr. Kathleen Moore, an internationally recognized leader in gynecologic oncology from the Stephenson Cancer Center, who breaks down what you need to know about where treatment is heading.

What to expect:

  • Understand Platinum Resistance: Learn what this diagnosis means and how it shapes your treatment options
  • Discover Emerging Therapies: Hear about the promise of antibody-drug conjugates (ADCs) and other new drugs that are improving survival
  • Learn About Biomarker Testing: Find out how tests for markers like folate receptor and BRCA can unlock personalized treatment paths
  • Explore Clinical Trials: Get clear answers about how to find and access clinical trials for new and promising ovarian cancer treatments
  • Personalize Your Care: Learn how oncologists are sequencing therapies to create more effective, individualized treatment plans
  • Advocate for Yourself: Gain insights on communicating with your doctor and the questions to ask to ensure you get the best care
ovarian cancer treatments webinar with Dr. Kathleen Moore
Register for this informative program then invite a Friend or Care Partner.

 

A New Era in Ovarian Cancer Treatment and Platinum-Resistant Options
Hosted by The Patient Story Team
Navigating a diagnosis of platinum-resistant ovarian cancer can feel overwhelming, but recent advancements and clinical trials are bringing new hope and more personalized treatment paths. This program offers empowering information on the latest therapies. We are joined by Dr. Kathleen Moore, an internationally recognized leader in gynecologic oncology from the Stephenson Cancer Center, who breaks down what you need to know about where treatment is heading.
Powered by
Powered by

Thank you to AbbVie for its support of our independent patient education program. The Patient Story retains full editorial control over all content.

Categories
Follicular Lymphoma Patient Events

Your Follicular Lymphoma Questions, Answered by Dr. Peter Martin

Your Follicular Lymphoma Questions, Answered by Dr. Peter Martin

Collecting questions for a limited time: Register now to get your question submitted in time!

Living with follicular lymphoma often comes with more questions than answers. That’s why we’re turning directly to the community — and a leading follicular lymphoma expert — to help.
 
For a limited time, we’re collecting your most important questions about living with and treating follicular lymphoma for Dr. Peter Martin from Weill Cornell Medicine. We’ll present his expert answers in a special webinar hosted by The Patient Story.

What to expect:

  • We’re gathering questions from the follicular lymphoma community for a limited time.
  • Dr. Martin will answer as many as possible during the webinar.
  • Please note: Due to the number of registrants, not every question can be addressed individually.
  • Answers will be provided in general terms and not personalized medical advice. For your specific situation, always consult your own physician and care team.
follicular lymphoma top questions answered by Dr. Peter Martin Weill Cornell Medicine

A special thanks to our friends at the Living with Follicular Lymphoma Facebook Group for their partnership. Their private Facebook group is dedicated to supporting individuals with follicular lymphoma, their families, and supporters. They offer a safe space to share personal experiences, learn about the latest research, trials, and treatments.

Register for this informative program then invite a Friend or Care Partner.

 

Your Follicular Lymphoma Questions, Answered by Dr. Peter Martin
Hosted by The Patient Story Team
Living with follicular lymphoma often comes with more questions than answers. That’s why we’re turning directly to the community — and a leading follicular lymphoma expert — to help. For the next two weeks, we’re collecting your most important questions about living with and treating follicular lymphoma for Dr. Peter Martin from Weill Cornell Medicine. We’ll present his expert answers in a special webinar hosted by The Patient Story.
Powered by
Powered by
Categories
DLBCL Patient Events

Looking to the Future: Treatment Paths for Relapsed/Refractory DLBCL

Looking to the Future: Treatment Paths for Relapsed/Refractory DLBCL

Plus: How Academic & Community Hospitals Work Together for You

For people facing relapsed or refractory DLBCL, the path forward can feel uncertain and overwhelming trying to weigh treatment options.

That’s why this program brings together Dr. Joshua Brody from Mount Sinai and Dr. Amir Steinberg from Westchester Medical Center, two lymphoma specialists who coordinate closely across academic and community settings. Moderated by The Patient Story’s own founder and DLBCL survivor, Stephanie Chuang, they’ll share how new therapies are changing the landscape and how working together across systems helps ensure patients have access to the most up-to-date treatments and support.

Topics:

  • What relapsed/refractory DLBCL means for patients

  • Latest treatment advances and what they could mean for care

  • How academic and community oncologists collaborate on patient treatment

  • Clinical trial opportunities and why they matter

  • Practical tips for patients to advocate for themselves and ask the right questions

  • What the future may hold for people living with DLBCL

Dr. Joshua Brody and Dr. Amir Steinberg with DLBCL advocate Stephanie Chuang

Thank you to Genmab and AbbVie for their support of our patient education program. The Patient Story retains full editorial control over all content.

Register for this informative program then invite a Friend or Care Partner.

 

Looking to the Future: Treatment Paths for Relapsed/Refractory DLBCL
Hosted by The Patient Story Team
Hear Dr. Joshua Brody and Dr. Amir Steinberg discuss new treatments for relapsed/refractory DLBCL and how academic–community collaboration helps patients access the best care. Moderated by DLBCL Advocate Stephanie Chuang.
Powered by
Powered by
Categories
Endometrial Cancer Patient Events Urological

Advanced Endometrial Cancer: Making Informed Treatment Decisions and Accessing Clinical Trials

Advanced Endometrial Cancer

Making Informed Treatment Decisions and Accessing Clinical Trials

Endometrial cancer is the most common gynecologic cancer—and for many people, it comes with more questions than answers. In this honest, expert-led conversation, Dr. Brian Slomovitz from Mount Sinai Medical Center in Florida and The Patient Story’s Stephanie Chuang break down the latest in diagnosis, treatment options, and how to have better conversations with your care team.

Learn about early warning signs, key risk factors like obesity and PCOS, and how biomarker testing and clinical trials are changing the standard of care—especially for advanced and recurrent disease.

Topics:

  • Warning signs and symptoms to watch for, including post-menopausal bleeding
  • Risk factors that raise your chances, like obesity, PCOS, and Lynch syndrome
  • How specialists use biomarker testing to personalize care
  • Treatment options beyond chemotherapy, including immunotherapy and hormone therapy
  • What clinical trials are, who they’re for, and how to access them—even remotely
  • Why it’s okay (and important) to get a second or third opinion
Dr. Brian Slomovitz and Patient Advocate Stephanie Chuang

Thank you to Karyopharm for its support of our patient education program. The Patient Story retains full editorial control over all content.

Register for this informative program then invite a Friend or Care Partner.

 

Advanced Endometrial Cancer: Making Informed Treatment Decisions and Accessing Clinical Trials
Hosted by The Patient Story Team
Advanced endometrial cancer is not one-size-fits-all. In this free educational program, expert Dr. Brian Slomovitz joins The Patient Story to explain how biomarker testing, new therapies, and clinical trials are giving patients more options than ever before.
Powered by
Powered by
Categories
Blood Tests Medical Tests Myelofibrosis Myeloproliferative neoplasms (MPNs) Patient Events

MPN Lab Results: Feel More Confident Reading Your Labs

MPN Lab Results: Feel More Confident Reading Your Labs

Join an expert-led webinar - Pick a date and time that works best for you.

If you’re living with an MPN—like polycythemia vera, essential thrombocythemia, or myelofibrosis—your blood work plays a key role in both diagnosis and ongoing care. This program explains how lab results help guide treatment decisions, track disease changes, and manage symptoms or side effects over time.

Join Dr. Aaron Gerds of Cleveland Clinic and longtime MPN patient advocate Ruth Fein Revell as they explore how mutation testing—including JAK2, CALR, and MPL—can shape care, what trends to watch in your lab results, and how to have more confident conversations with your doctor.

Topics:

  • What CBC, CMP, and mutation testing reveal in MPNs

  • How doctors use blood work to monitor disease and guide treatment

  • Understanding JAK2, CALR, and MPL mutations

  • What allele burden means—and how it changes over time

  • When a bone marrow biopsy is needed (and when it might not be)

  • How to talk with your doctor about labs, results, and treatment options

Thank you to The Leukemia & Lymphoma Society for their partnership. The Leukemia & Lymphoma Society is here for you with information about clinical trials, resources, and dedicated support through their Information Specialists.

Register for this informative program then invite a Friend or Care Partner.

Whether you’ve just been diagnosed with ET, PV, or myelofibrosis or have been living with a myeloproliferative neoplasm for years, this conversation is for you.

 

MPN Lab Results: Feel More Confident Reading Your Labs
Hosted by The Patient Story Team
Blood work is essential in diagnosing and managing MPNs—but most patients are never taught what the numbers mean. In this program, Dr. Aaron Gerds of Cleveland Clinic breaks down key lab tests, explaining how doctors use them to make decisions about diagnosis, treatment, and monitoring.
Powered by
Powered by
Categories
Medical Tests Patient Events Waldenström’s Macroglobulinemia

Waldenström’s: What IgM and Other Lab Markers Tell Us

Waldenström’s Lab Tests Revealed: What IgM and Other Lab Markers Tell Us

Join an expert-led webinar - Pick a date and time that works best for you.

Join one of the world’s leading WM experts, Dr. Stephen Ansell of Mayo Clinic, in a conversation with patient advocate Annmarie Seldon. Together, they offer practical insights on how to interpret your results and what questions to ask at your next appointment. Whether you’re newly diagnosed, in active treatment, or navigating remission, this program will help you better understand your disease and feel more confident managing it.

Topics:

  • What IgM, hemoglobin, and other markers reveal in WM
  • Role of MYD88 and CXCR4 in confirming diagnosis and guiding care
  • How doctors decide when it’s time to begin treatment
  • Tracking treatment response through changes in bloodwork
  • What MRD means and where it fits in the future of WM care
  • Why ongoing lab monitoring is key—even in remission
Dr. Stephen Ansell from Mayo Clinic and Annmarie Seldon - Waldenstrom patient advocate

Thank you to The Leukemia & Lymphoma Society for their partnership. The Leukemia & Lymphoma Society is here for you with information about clinical trials, resources, and dedicated support through their Information Specialists.

Register for this informative program then invite a Friend or Care Partner.

Whether you’ve just been diagnosed or have been living with waldenström macroglobulinemia (WM) for years, this conversation is for you.

 

Waldenström’s: What IgM and Other Lab Markers Tell Us
Hosted by The Patient Story Team
In this expert-led session, Dr. Stephen Ansell of Mayo Clinic breaks down how lab results like IgM, genetic mutations, and CBC results inform diagnosis, treatment timing, and monitoring in Waldenström’s.
Powered by
Powered by
Categories
CLL Patient Events

CLL Lab Tests Revealed: Navigating Care with Confidence

CLL Lab Tests Revealed: Navigating Care with Confidence

Join an expert-led webinar - Pick the date and time that works best for you.

For many living with CLL, lab tests are a constant part of the experience—but understanding what they mean isn’t always easy. In this in-depth conversation, CLL expert Dr. Adam Kittai joins longtime patient advocate Michele Nadeem-Baker to explore how blood tests guide real-world care decisions.

From identifying when “watch and wait” should shift to active treatment, to interpreting genetic markers like IGHV and TP53, to understanding MRD testing and remission—this discussion helps demystify what’s behind the numbers and how they shape your care.

Topics:

  • How ongoing blood tests guide CLL monitoring and treatment timing

  • What genetic tests like IGHV, TP53, and FISH reveal about your prognosis

  • How MRD (minimal residual disease) testing is used to assess remission

  • Differences in follow-up for time-limited vs. continuous treatment

  • Questions to ask about your labs—and what they mean for your future care

CLL lab tests explained by Dr. Adam Kittai of Mount Sinai

Thank you to The Leukemia & Lymphoma Society for their partnership. The Leukemia & Lymphoma Society is here for you with information about clinical trials, resources, and dedicated support through their Information Specialists.

Register for this informative program then invite a Friend or Care Partner.

Whether you’ve just been diagnosed or have been living with CLL for years, this conversation is for you.

 

CLL Labs Revealed: Navigating Care with Confidence
Hosted by The Patient Story Team
What do your CLL blood test results actually mean? In this educational program, Dr. Adam Kittai and CLL patient advocate Michele Nadeem-Baker explain how common tests—like CBC, IGHV, and MRD—help guide diagnosis, treatment, and prognosis.
Powered by
Powered by
Categories
Follicular Lymphoma Non-Hodgkin Lymphoma Patient Events

Follicular Lymphoma Lab Tests Explained with Dr. Celeste Bello

Follicular Lymphoma Lab Tests Explained: How Blood, Biopsy, and Imaging Tests Impact Treatment Decisions

Join an expert-led webinar - Pick the date and time that works best for you.

How do blood test results help guide care for follicular lymphoma (FL)? What do terms like CBC, LDH, beta-2 microglobulin, and FLIPI really mean—and how are they used in monitoring and treatment planning?

In this in-depth discussion, Stephanie Chuang speaks with FL expert Dr. Celeste Bello of Moffitt Cancer Center. Together, they walk through the most important blood work and imaging tools in FL, when and how they’re used. They cover what biopsy types matter most, and how criteria like FLIPI, POD24, and GELF help determine when to start treatment. 

Topics:

  • What blood tests and scans reveal in FL—and when they matter most

  • Biopsies and diagnostic tools: flow cytometry, IHC, and imaging

  • Understanding prognostic tools like FLIPI, POD24, and GELF criteria

  • Monitoring during observation and treatment: labs, scans, and red flags

  • Why speaking up about subtle changes can shape your care plan

Dr. Celeste Bello breaks down follicular lymphoma lab markers

Thank you to The Leukemia & Lymphoma Society for their partnership. The Leukemia & Lymphoma Society is here for you with information about clinical trials, resources, and dedicated support through their Information Specialists.

Register for this informative program then invite a Friend or Care Partner.

This program is designed to empower patients and care partners with clarity around tests—and when to speak up.

 

Follicular Lymphoma: Your Lab Tests Explained
Hosted by The Patient Story Team
Explore how blood tests, biopsies, and scans guide follicular lymphoma care—from diagnosis and observation to active treatment. Dr. Celeste Bello breaks down what lab markers really mean and when to act on them.
Powered by
Powered by